{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:28:04Z","timestamp":1793896084568,"version":"4.8.0"},"reference-count":91,"publisher":"Bentham Science Publishers Ltd.","issue":"5","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Ankylosing spondylitis (AS) is a chronic inflammatory disease known\nfor causing pain, stiffness, and reduced mobility in the axial skeleton. Adalimumab, a tumor necrosis\nfactor (TNF) inhibitor, has emerged as a promising therapeutic option for AS.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This systematic review involved a comprehensive search of randomized controlled\ntrials related to AS treatment, conducted in major databases such as MEDLINE, Google Scholar,\nand PubMed. The search terms encompassed ankylosing spondylitis, adalimumab, methotrexate,\nother non-biologic DMARDs, glucocorticoids, NSAIDs, and analgesics. A total of 14 randomized\ncontrolled trials with 4,500 participants were included in the review.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The review's results revealed that adalimumab demonstrated notable superiority when\ncompared to a placebo. It effectively reduced disease activity, improved physical function, and\nlowered inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate.\nAdalimumab demonstrated a favorable safety profile, with adverse events comparable to those observed\nwith placebo.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Based on the results, adalimumab is deemed an effective treatment for AS, showcasing\nits potential as a first-line therapeutic option. Notably, no significant increase in adverse\nevents was observed compared to placebo. However, the conclusion emphasizes the need for further\nstudies with extended follow-up durations to ascertain the long-term efficacy and safety of\nadalimumab in AS management. This systematic review provides valuable insights supporting the\nuse of adalimumab in the treatment of AS and underscores the importance of ongoing investigations\ninto its long-term effects to optimize its clinical utilization in AS patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115733971289295240223095751","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T04:31:42Z","timestamp":1709267502000},"page":"501-513","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An Overview of Adalimumab Therapy for Ankylosing Spondylitis"],"prefix":"10.2174","volume":"20","author":[{"given":"Anna M.","family":"Sukhanova","sequence":"first","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"},{"name":"Moscow Research and Practical Centre on Addictions of Moscow, Department of Public Health,\n37\/1 Lyublinskaya Str., 109390 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam A.","family":"Gilavian","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta V.","family":"Melnik","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia V.","family":"Shikh","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey E.","family":"Petukhov","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"},{"name":"Moscow Research and Practical Centre on Addictions of Moscow, Department of Public Health,\n37\/1 Lyublinskaya Str., 109390 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir I.","family":"Gegechkori","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey P.","family":"Dementev","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Vlasov","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina V.","family":"Ramenskaya","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical\nUniversity of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991\nMoscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/OARRR.S44550","volume":"6","author":"(a) Maghraoui E.A.","year":"2014","unstructured":"(a) Maghraoui E.A.; Mounach A.; Efficacy and safety of adalimumab in ankylosing spondylitis. Open Access Rheumatol  2014,6,83-90","journal-title":"Open Access Rheumatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40259-020-00408-z","volume":"34","author":"Su J.","year":"2020","unstructured":"Su J.; Li M.; He L.; Zhao D.; Wan W.; Liu Y.; Xu J.; Xu J.; Liu H.; Jiang L.; Wu H.; Zuo X.; Huang C.; Liu X.; Li F.; Zhang Z.; Liu X.; Dong L.; Li T.; Chen H.; Li J.; He D.; Lu X.; Huang A.; Tao Y.; Wang Y.; Zhang Z.; Wei W.; Li X.; Zeng X.; Comparison of the efficacy and safety of adalimumab (Humira) and the adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis: A multicenter, randomized, double-blind, parallel, phase III clinical trial. BioDrugs  2020,34(3),381-393","journal-title":"BioDrugs"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5152\/eurasianjmed.2017.17116","volume":"49","author":"Uckun A.","year":"2017","unstructured":"Uckun A.; Sezer I.; Ankylosing spondylitis and balance. Eurasian J Med  2017,49(3),207-210","journal-title":"Eurasian J Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/1471-2474-13-243","volume":"13","author":"Cooksey R.","year":"2012","unstructured":"Cooksey R.; Brophy S.; Husain M.J.; Irvine E.; Davies H.; Siebert S.; The information needs of people living with ankylosing spondylitis: A questionnaire survey. BMC Musculoskelet Disord  2012,13(1),243","journal-title":"BMC Musculoskelet Disord"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.aott.2016.06.010","volume":"50","author":"Saglam Y.","year":"2016","unstructured":"Saglam Y.; Ozturk I.; Cakmak M.F.; Ozdemir M.; Yazicioglu O.; Total hip arthroplasty in patients with ankylosing spondylitis: Midterm radiologic and functional results. Acta Orthop Traumatol Turc  2016,50(4),443-447","journal-title":"Acta Orthop Traumatol Turc"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/acr.23582","volume":"71","author":"Ward M.M.","year":"2019","unstructured":"Ward M.M.; Complications of total hip arthroplasty in patients with ankylosing spondylitis. Arthritis Care Res  2019,71(8),1101-1108","journal-title":"Arthritis Care Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1302\/2058-5241.4.180047","volume":"4","author":"Lin D.","year":"2019","unstructured":"Lin D.; Charalambous A.; Hanna S.A.; Bilateral total hip arthroplasty in ankylosing spondylitis: A systematic review. EFORT Open Rev  2019,4(7),476-481","journal-title":"EFORT Open Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/rheumatology\/kev340","volume":"55","author":"Webers C.","year":"2015","unstructured":"Webers C.; Essers I.; Ramiro S.; Stolwijk C.; Landew\u00e9 R.; van der Heijde D.; van den Bosch F.; Dougados M.; van Tubergen A.; Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatology  2015,55(3),419-428","journal-title":"Rheumatology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s10067-013-2278-3","volume":"32","author":"Guan M.","year":"2013","unstructured":"Guan M.; Wang J.; Zhao L.; Xiao J.; Li Z.; Shi Z.; Management of hip involvement in ankylosing spondylitis. Clin Rheumatol  2013,32(8),1115-1120","journal-title":"Clin Rheumatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1054\/arth.2001.19160","volume":"16","author":"Joshi A.","year":"2001","unstructured":"Joshi A.; Ilchmann T.; Markovic L.; Socket wear in bilateral simultaneous total hip arthroplasty. J Arthroplasty  2001,16(1),117-120","journal-title":"J Arthroplasty"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3944\/AOTT.2013.3103","volume":"47","author":"Ulu\u00e7ay C.","year":"2013","unstructured":"Ulu\u00e7ay C.; Ozler T.; G\u00fcven M.; Akman B.; Kocadal A.O.; Alt\u0131nta\u015f F.; Etiology of coxarthrosis in patients with total hip replacement. Acta Orthop Traumatol Turc  2013,47(5),330-333","journal-title":"Acta Orthop Traumatol Turc"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10067-011-1819-x","volume":"31","author":"Yacoub I.Y.","year":"2012","unstructured":"Yacoub I.Y.; Amine B.; Laatiris A.; Hassouni H.N.; Gender and disease features in Moroccan patients with ankylosing spondylitis. Clin Rheumatol  2012,31(2),293-297","journal-title":"Clin Rheumatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s10067-016-3431-6","volume":"35","author":"He C.","year":"2016","unstructured":"He C.; He X.; Tong W.; Zheng W.; Zhang T.; Zhao J.; Xu W.; The effect of total hip replacement on employment in patients with ankylosing spondylitis. Clin Rheumatol  2016,35(12),2975-2981","journal-title":"Clin Rheumatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/annrheumdis-2013-203963","volume":"73","author":"Nystad T.W.","year":"2014","unstructured":"Nystad T.W.; Furnes O.; Havelin L.I.; Hip replacement surgery in patients with ankylosing spondylitis. Ann Rheum Dis  2014,73,1194-1197","journal-title":"Ann Rheum Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/os.12254","volume":"8","author":"Feng D.","year":"2016","unstructured":"Feng D.; Zhang K.; Zhang Y.; Nian Y.; Zhang J.; Kang X.; Wu S.; Zhu Y.; Bilaterally primary cementless total hip arthroplasty for severe hip ankylosis with ankylosing spondylitis. Orthop Surg  2016,8(3),352-359","journal-title":"Orthop Surg"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s10067-014-2575-5","volume":"33","author":"Zhang L.","year":"2014","unstructured":"Zhang L.; Yang D.; Yin X.; Zhou Y.; Risk factors for poor hip flexion after total hip arthroplasty for the treatment of ankylosing spondylitis a multivariate analysis. Clin Rheumatol  2014,33(9),1295-1301","journal-title":"Clin Rheumatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.arth.2018.08.025","volume":"34","author":"Gautam D.","year":"2019","unstructured":"Gautam D.; Malhotra R.; Total hip arthroplasty in ankylosing spondylitis with extension contracture of hips. J Arthroplasty  2019,34(1),71-76","journal-title":"J Arthroplasty"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.21823\/2311-2905-2016-0-2-70-79","volume":"22","author":"Tikhilov R.M.","year":"2016","unstructured":"Tikhilov R.M.; Nikolaev N.S.; Shubnyakov I.I.; Myasoedov A.A.; Boyarov A.A.; Efimov A.V.; Syundyukov A.R.; Difficulties of total hip replacement in patients with ankylosing spondylitis (case report). Traumatol Orthop Russia  2016,22(2),70-79","journal-title":"Traumatol Orthop Russia"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/rheumatology\/key079","volume":"57","author":"Braun J.","year":"2018","unstructured":"Braun J.; Axial spondyloarthritis including ankylosing spondylitis. Rheumatology  2018,57(S6),vi1-vi3","journal-title":"Rheumatology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.5535\/arm.2013.37.5.675","volume":"37","author":"Cho H.","year":"2013","unstructured":"Cho H.; Kim T.; Kim T.H.; Lee S.; Lee K.H.; Spinal mobility, vertebral squaring, pulmonary function, pain, fatigue, and quality of life in patients with ankylosing spondylitis. Ann Rehabil Med  2013,37(5),675-682","journal-title":"Ann Rehabil Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3892\/mmr.2017.6248","volume":"15","author":"Chen B.","year":"2017","unstructured":"Chen B.; Li J.; He C.; Li D.; Tong W.; Zou Y.; Xu W.; Role of HLA-B27 in the pathogenesis of ankylosing spondylitis. Mol Med Rep  2017,15(4),1943-1951","journal-title":"Mol Med Rep"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00296-017-3741-2","volume":"37","author":"Lin H.","year":"2017","unstructured":"Lin H.; Gong Y.Z.; Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: A meta-analysis. Rheumatol Int  2017,37(8),1267-1280","journal-title":"Rheumatol Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13075-018-1724-7","volume":"20","author":"Ar\u00e9valo M.","year":"2018","unstructured":"Ar\u00e9valo M.; Masmitj\u00e0 G.J.; Moreno M.; Calvet J.; Orellana C.; Ruiz D.; Castro C.; Carreto P.; Larrosa M.; Collantes E.; Font P.; Influence of HLA-B27 on the ankylosing spondylitis phenotype: Results from the REGISPONSER database. Arthritis Res Ther  2018,20(1),221","journal-title":"Arthritis Res Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1179544117751627","DOI":"10.1177\/1179544117751627","volume":"11","author":"Akassou A.","year":"2018","unstructured":"Akassou A.; Bakri Y.; Does HLA-B27 status influence ankylosing spondylitis phenotype? Clin Med Insights Arthritis Musculoskelet Disord  2018,11,1179544117751627","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"Sieper J.","year":"2017","unstructured":"Sieper J.; Poddubnyy D.; Axial spondyloarthritis. Lancet  2017,390(10089),73-84","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"Taurog J.D.","year":"2016","unstructured":"Taurog J.D.; Chhabra A.; Colbert R.A.; Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med  2016,374(26),2563-2574","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.3892\/etm.2020.8564","volume":"19","author":"Fan M.","year":"2020","unstructured":"Fan M.; Liu J.; Zhao B.; Wu X.; Li X.; Gu J.; Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med  2020,19(4),3031-3041","journal-title":"Exp Ther Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40744-020-00248-x","volume":"7","author":"Karmacharya P.","year":"2020","unstructured":"Karmacharya P.; Shahukhal R.; Crowson C.S.; Murad M.H.; Davis J.M.; Shrestha P.; Bekele D.; Wright K.; Chakradhar R.; Dubreuil M.; Effects of therapies on cardiovascular events in ankylosing spondylitis: A systematic review and meta-analysis. Rheumatol Ther  2020,7(4),993-1009","journal-title":"Rheumatol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3899\/jrheum.190299","volume":"47","author":"George M.D.","year":"2020","unstructured":"George M.D.; Baker J.F.; Ogdie A.; Comparative persistence of methotrexate and tumor necrosis factor inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol  2020,47(6),826-834","journal-title":"J Rheumatol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-019-1908-9","volume":"21","author":"Lindstr\u00f6m U.","year":"2019","unstructured":"Lindstr\u00f6m U.; Olofsson T.; Wedr\u00e9n S.; Qirjazo I.; Askling J.; Biological treatment of ankylosing spondylitis: A nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther  2019,21(1),128","journal-title":"Arthritis Res Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/03946320140270S102","volume":"27","author":"Armuzzi A.","year":"2014","unstructured":"Armuzzi A.; Lionetti P.; Blandizzi C.; Caporali R.; Chimenti S.; Cimino L.; Gionchetti P.; Girolomoni G.; Lapadula G.; Marchesoni A.; Marcellusi A.; Mennini F.S.; Salvarani C.; Cimaz R.; anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol  2014,27(S1),11-32","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcph.1348","volume":"59","author":"Wro\u0144ski J.","year":"2019","unstructured":"Wro\u0144ski J.; Fiedor P.; The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: Are TNF inhibitors safer than we thought? J Clin Pharmacol  2019,59(4),445-462","journal-title":"J Clin Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3899\/jrheum.150389","volume":"42","author":"Heinonen A.V.","year":"2015","unstructured":"Heinonen A.V.; Aaltonen K.J.; Joensuu J.T.; L\u00e4hteenm\u00e4ki J.P.; Pertovaara M.I.; Romu M.K.; Hirvonen H.E.; Simil\u00e4 A.K.; Blom M.L.; Nordstr\u00f6m D.C.; Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: A prospective cohort study. J Rheumatol  2015,42(12),2339-2346","journal-title":"J Rheumatol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","volume":"33","author":"Machado M.A.\u00c1.","year":"2013","unstructured":"Machado M.A.\u00c1.; Barbosa M.M.; Almeida A.M.; de Ara\u00fajo V.E.; Kakehasi A.M.; Andrade E.I.G.; Cherchiglia M.L.; Acurcio F.A.; Treatment of ankylosing spondylitis with TNF blockers: A meta-analysis. Rheumatol Int  2013,33(9),2199-2213","journal-title":"Rheumatol Int"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"Haroon N.","year":"2013","unstructured":"Haroon N.; Inman R.D.; Learch T.J.; Weisman M.H.; Lee M.; Rahbar M.H.; Ward M.M.; Reveille J.D.; Gensler L.S.; The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum  2013,65(10),2645-2654","journal-title":"Arthritis Rheum"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12016-017-8623-6","volume":"54","author":"Hou L.","year":"2018","unstructured":"Hou L.; Jiang G.; Chen Y.; Yang X.M.; Meng L.; Xue M.; Liu X.; Chen X.; Li X.; The comparative safety of TNF inhibitors in ankylosing spondylitis\u2014a meta-analysis update of 14 randomized controlled trials. Clin Rev Allergy Immunol  2018,54(2),234-243","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"Burmester G.R.","year":"2013","unstructured":"Burmester G.R.; Panaccione R.; Gordon K.B.; McIlraith M.J.; Lacerda A.P.M.; Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis  2013,72(4),517-524","journal-title":"Ann Rheum Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/OARRR.S32582","volume":"43","author":"Murdaca G.G.","year":"2013","unstructured":"Murdaca G.G.; Span\u00e0 F.; Puppo F.; Long-term treatment of rheumatoid arthritis with adalimumab. Open Access Rheumatol  2013,43,43","journal-title":"Open Access Rheumatol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpeds.2018.05.042","volume":"201","author":"Horneff G.","year":"2018","unstructured":"Horneff G.; Seyger M.M.B.; Arikan D.; Kalabic J.; Anderson J.K.; Lazar A.; Williams D.A.; Wang C.; Potempa Y.R.; Hyams J.S.; Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and crohn\u2019s disease. J Pediatr  2018,201,166-175.e3","journal-title":"J Pediatr"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3389\/fphar.2019.01497","volume":"10","author":"D\u2019Angelo S.","year":"2019","unstructured":"D\u2019Angelo S.; Cantini F.; Ramonda R.; Cantarini L.; Carletto A.; Chimenti M.S.; Sedie D.A.; Foti R.; Gerli R.; Lomater C.; Lubrano E.; Marchesoni A.; Zabotti A.; Salvarani C.; Scrivo R.; Scarpa R.; Tramontano G.; Nannini C.; Lorenzin M.; Fabbroni M.; Martinis F.; Perricone R.; Carli L.; Visalli E.; Rovera G.; Perrotta F.M.; Quartuccio L.; Altobelli A.; Costa L.; Niccoli L.; Ortolan A.; Caso F.; Effectiveness of adalimumab for the treatment of psoriatic arthritis: An italian real-life retrospective study. Front Pharmacol  2019,10,1497","journal-title":"Front Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"Reich K.","year":"2019","unstructured":"Reich K.; Gooderham M.; Tha\u00e7i D.; Crowley J.J.; Ryan C.; Krueger J.G.; Tsai T.F.; Flack M.; Gu Y.; Williams D.A.; Thompson E.H.Z.; Paul C.; Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet  2019,394(10198),576-586","journal-title":"Lancet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"CD012878","DOI":"10.1002\/14651858.CD012878.pub2","volume":"2019","author":"Abbass M.","year":"2019","unstructured":"Abbass M.; Cepek J.; Parker C.E.; Nguyen T.M.; MacDonald J.K.; Feagan B.G.; Khanna R.; Jairath V.; Adalimumab for induction of remission in Crohn\u2019s disease. Cochrane Libr  2019,2019(11),CD012878","journal-title":"Cochrane Libr"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bcp.12509","volume":"79","author":"Ternant D.","year":"2015","unstructured":"Ternant D.; Ducourau E.; Fuzibet P.; Vignault C.; Watier H.; Lequerr\u00e9 T.; Le Lo\u00ebt X.; Vittecoq O.; Goupille P.; Mulleman D.; Paintaud G.; Pharmacokinetics and concentration\u2013effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol  2015,79(2),286-297","journal-title":"Br J Clin Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s10067-014-2498-1","volume":"33","author":"Kingsbury D.J.","year":"2014","unstructured":"Kingsbury D.J.; Bader-Meunier B.; Patel G.; Arora V.; Kalabic J.; Kupper H.; Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol  2014,33(10),1433-1441","journal-title":"Clin Rheumatol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","volume":"34","author":"Lemos L.L.P.","year":"2014","unstructured":"Lemos L.L.P.; de Costa O.J.; Almeida A.M.; Junior H.O.; Barbosa M.M.; Kakehasi A.M.; Acurcio F.A.; Treatment of psoriatic arthritis with anti-TNF agents: A systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int  2014,34(10),1345-1360","journal-title":"Rheumatol Int"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/annrheumdis-2014-206588","volume":"74","author":"Vogelzang E.H.","year":"2015","unstructured":"Vogelzang E.H.; Pouw M.F.; Nurmohamed M.; Kneepkens E.L.; Rispens T.; Wolbink G.J.; Krieckaert C.L.M.; Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs. Ann Rheum Dis  2015,74(2),474-475","journal-title":"Ann Rheum Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2040622318772705","volume":"9","author":"Sator P.","year":"2018","unstructured":"Sator P.; Safety and tolerability of adalimumab for the treatment of psoriasis: A review summarizing 15 years of real-life experience. Ther Adv Chronic Dis  2018,9(8),147-158","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s40265-015-0503-x","volume":"75","author":"Burness C.B.","year":"2015","unstructured":"Burness C.B.; McKeage K.; Adalimumab: A review in chronic plaque psoriasis. Drugs  2015,75(18),2119-2130","journal-title":"Drugs"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","volume":"12","author":"Colombel J.F.","year":"2014","unstructured":"Colombel J.F.; Rutgeerts P.J.; Sandborn W.J.; Yang M.; Camez A.; Pollack P.F.; Thakkar R.B.; Robinson A.M.; Chen N.; Mulani P.M.; Chao J.; Adalimumab induces deep remission in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol  2014,12(3),414-422.e5","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.3390\/ijms19082244","volume":"19","author":"Adegbola S.O.","year":"2018","unstructured":"Adegbola S.O.; Sahnan K.; Warusavitarne J.; Hart A.; Tozer P.; Anti-TNF therapy in crohn\u2019s disease. Int J Mol Sci  2018,19(8),2244","journal-title":"Int J Mol Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","volume":"67","author":"Bouhnik Y.","year":"2018","unstructured":"Bouhnik Y.; Carbonnel F.; Laharie D.; Stefanescu C.; H\u00e9buterne X.; Abitbol V.; Nachury M.; Brixi H.; Bourreille A.; Picon L.; Bourrier A.; Allez M.; Peyrin-Biroulet L.; Moreau J.; Savoye G.; Fumery M.; Nancey S.; Roblin X.; Altwegg R.; Bouguen G.; Bommelaer G.; Danese S.; Louis E.; Zappa M.; Mary J.Y.; Efficacy of adalimumab in patients with Crohn\u2019s disease and symptomatic small bowel stricture: A multicentre, prospective, observational cohort (CREOLE) study. Gut  2018,67(1),53-60","journal-title":"Gut"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","volume":"383","author":"Smolen J.S.","year":"2014","unstructured":"Smolen J.S.; Emery P.; Fleischmann R.; van Vollenhoven R.F.; Pavelka K.; Durez P.; Gu\u00e9rette B.; Kupper H.; Redden L.; Arora V.; Kavanaugh A.; Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled OPTIMA trial. Lancet  2014,383(9914),321-332","journal-title":"Lancet"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"Jang D.","year":"2021","unstructured":"Jang D.; Lee A.H.; Shin H.Y.; Song H.R.; Park J.H.; Kang T.B.; Lee S.R.; Yang S.H.; The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci  2021,22(5),2719","journal-title":"Int J Mol Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/imt-2022-0181","volume":"15","author":"Haranaka M.","year":"2023","unstructured":"Haranaka M.; Tanaka T.; Kim S.; Bae Y.; Jeon D.; Choi E.; Cha J.; Lee S.; Ogama Y.; Pharmacokinetics and safety of CT-P17 (40 mg\/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Immunotherapy  2023,15(3),149-161","journal-title":"Immunotherapy"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"Huang F.","year":"2014","unstructured":"Huang F.; Gu J.; Zhu P.; Bao C.; Xu J.; Xu H.; Wu H.; Wang G.; Shi Q.; Andhivarothai N.; Anderson J.; Pangan A.L.; Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis  2014,73(3),587-594","journal-title":"Ann Rheum Dis"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/acr.22191","volume":"66","author":"Terslev L.","year":"2014","unstructured":"Terslev L.; Naredo E.; Iagnocco A.; Balint P.V.; Wakefield R.J.; Aegerter P.; Aydin S.Z.; Bachta A.; Hammer H.B.; Bruyn G.A.W.; Filippucci E.; Gandjbakhch F.; Mandl P.; Pineda C.; Schmidt W.A.; D\u2019Agostino M.A.; Defining enthesitis in spondyloarthritis by ultrasound: Results of a Delphi process and of a reliability reading exercise. Arthritis Care Res  2014,66(5),741-748","journal-title":"Arthritis Care Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40744-021-00416-7","volume":"9","author":"Truong S.","year":"2022","unstructured":"Truong S.; McEwan T.; Bird P.; Lim I.; Saad N.; Schachna L.; Taylor A.M.; Robinson P.; Australian consensus statements for the assessment and management of non-radiographic axial spondyloarthritis. Rheumatol Ther  2022,9(1),1-24","journal-title":"Rheumatol Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40744-019-0146-6","volume":"6","author":"Robinson P.C.","year":"2019","unstructured":"Robinson P.C.; Sengupta R.; Siebert S.; Non-radiographic axial spondyloarthritis (nr-axSpA): Advances in classification, imaging and therapy. Rheumatol Ther  2019,6(2),165-177","journal-title":"Rheumatol Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11926-015-0535-y","volume":"17","author":"van der Linden S.","year":"2015","unstructured":"van der Linden S.; Akkoc N.; Brown M.A.; Robinson P.C.; Khan M.A.; The ASAS criteria for axial spondyloarthritis: Strengths, weaknesses, and proposals for a way forward. Curr Rheumatol Rep  2015,17(9),62","journal-title":"Curr Rheumatol Rep"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"Sieper J.","year":"2013","unstructured":"Sieper J.; van der Heijde D.; Dougados M.; Mease P.J.; Maksymowych W.P.; Brown M.A.; Arora V.; Pangan A.L.; Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis  2013,72(6),815-822","journal-title":"Ann Rheum Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/rheumatology\/keu438","volume":"54","author":"van der Heijde D.","year":"2015","unstructured":"van der Heijde D.; Breban M.; Halter D.; DiVittorio G.; Bratt J.; Cantini F.; Kary S.; Pangan A.L.; Kupper H.; Rathmann S.S.; Sieper J.; Mease P.J.; Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology  2015,54(7),1210-1219","journal-title":"Rheumatology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"Ward M.M.","year":"2016","unstructured":"Ward M.M.; Deodhar A.; Akl E.A.; Lui A.; Ermann J.; Gensler L.S.; Smith J.A.; Borenstein D.; Hiratzka J.; Weiss P.F.; Inman R.D.; Majithia V.; Haroon N.; Maksymowych W.P.; Joyce J.; Clark B.M.; Colbert R.A.; Figgie M.P.; Hallegua D.S.; Prete P.E.; Rosenbaum J.T.; Stebulis J.A.; van den Bosch F.; Yu D.T.Y.; Miller A.S.; Reveille J.D.; Caplan L.; American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol  2016,68(2),282-298","journal-title":"Arthritis Rheumatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"606497","DOI":"10.3389\/fphar.2020.606497","volume":"11","author":"Su J.","year":"2020","unstructured":"Su J.; Li M.; He L.; Zhao D.; Wan W.; Liu Y.; Xu J.; Xu J.; Liu H.; Jiang L.; Wu H.; Zuo X.; Huang C.; Liu X.; Li F.; Zhang Z.; Liu X.; Dong L.; Li T.; Chen H.; Li J.; He D.; Lu X.; Huang A.; Tao Y.; Wang Y.; Zhang Z.; Wei W.; Li X.; Zeng X.; Changes in efficacy indicators for adalimumab biosimilar candidate (HS016) for the treatment of active ankylosing spondylitis at various time points. Front Pharmacol  2020,11,606497","journal-title":"Front Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/14712598.2018.1430760","volume":"18","author":"Pelechas E.","year":"2018","unstructured":"Pelechas E.; Voulgari P.V.; Drosos A.A.; ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther  2018,18(3),317-322","journal-title":"Expert Opin Biol Ther"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2665-9913(19)30013-X","volume":"1","author":"Xu H.","year":"2019","unstructured":"Xu H.; Li Z.; Wu J.; Xing Q.; Shi G.; Li J.; Liu X.; Wu L.; Li X.; Tan W.; He D.; Bi L.; Li H.; Xiao Z.; Shuai Z.; Li X.; Wang Y.; Luo L.; Zheng Y.; Xiao W.; Wu X.; Zhou L.; Li T.; Qian L.; Zhou H.; Lu S.; Zheng S.; Xiong Y.; Wang X.; Wang Y.; Wu X.; IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: A randomised, double-blind, phase 3 equivalence trial. Lancet Rheumatol  2019,1(1),e35-e43","journal-title":"Lancet Rheumatol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14712598.2018.1468884","volume":"18","author":"Jones A.","year":"2018","unstructured":"Jones A.; Ciurtin C.; Ismajli M.; Leandro M.; Sengupta R.; Machado P.M.; Biologics for treating axial spondyloarthritis. Expert Opin Biol Ther  2018,18(6),641-652","journal-title":"Expert Opin Biol Ther"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrrheum.2015.110","volume":"11","author":"D\u00f6rner T.","year":"2015","unstructured":"D\u00f6rner T.; Kay J.; Biosimilars in rheumatology: Current perspectives and lessons learnt. Nat Rev Rheumatol  2015,11(12),713-724","journal-title":"Nat Rev Rheumatol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMhle1800125","volume":"378","author":"Lyman G.H.","year":"2018","unstructured":"Lyman G.H.; Zon R.; Harvey R.D.; Schilsky R.L.; Rationale, opportunities, and reality of biosimilar medications. N Engl J Med  2018,378(21),2036-2044","journal-title":"N Engl J Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7249\/PE264","volume":"7","author":"Mulcahy A.W.","year":"2017","unstructured":"Mulcahy A.W.; Hlavka J.P.; Case S.R.; Biosimilar cost savings in the United States: Initial experience and future potential. Rand Health Q  2017,7(4),3","journal-title":"Rand Health Q"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"J\u00f8rgensen K.K.","year":"2017","unstructured":"J\u00f8rgensen K.K.; Olsen I.C.; Goll G.L.; Lorentzen M.; Bolstad N.; Haavardsholm E.A.; Lundin K.E.A.; M\u00f8rk C.; Jahnsen J.; Kvien T.K.; Berset I.P.; Fevang B.T.S.; Florholmen J.; Kalstad S.; M\u00f8rk N.J.; Ryggen K.; Tveit K.S.; S\u00e6ther S.K.; Gulbrandsen B.; Hagfors J.; Waksvik K.; Warren D.; Henanger K.J.; Asak \u00d8.; Baigh S.; Blomgren I.M.; Bruun T.J.; Dvergsnes K.; Frigstad S.O.; Gjesdal C.G.; Grandaunet B.H.J.; Hansen I.M.; Hatten I.S.H.; Huppertz-Hauss G.; Henriksen M.; Hoie S.S.; Krogh J.; Kruse J.R.; Ljos\u00e5 M-K.A.; Midtgard I.P.; Mielnik P.; Moum B.; Noraberg G.; Poyan A.; Presteg\u00e5rd U.; Rashid H.U.; Rydning J.H.; Sagatun L.; Seeberg K.A.; Skjetne K.; Strand E.K.; Stray H.; Stray N.; Torp R.; Vold C.; Ystr\u00f8m C.M.; Zettel C.C.; Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. Lancet  2017,389(10086),2304-2316","journal-title":"Lancet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"Park W.","year":"2017","unstructured":"Park W.; Yoo D.H.; Miranda P.; Brzosko M.; Wiland P.; Ure\u00f1a G.S.; Mikazane H.; Lee Y.A.; Smiyan S.; Lim M.J.; Kadinov V.; Abud-Mendoza C.; Kim H.; Lee S.J.; Bae Y.; Kim S.; Braun J.; Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis  2017,76(2),346-354","journal-title":"Ann Rheum Dis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3390\/jcm8070956","volume":"8","author":"Evripidis K.","year":"2019","unstructured":"Evripidis K.; Eleftherios P.; Paraskevi V.V.; Alexandros D.A.; Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: An 18-month comparative open-label study. J Clin Med  2019,8(7),956","journal-title":"J Clin Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10067-021-05943-w","volume":"41","author":"Su J.","year":"2022","unstructured":"Su J.; Li M.; He L.; Zhao D.; Wan W.; Liu Y.; Xu J.; Xu J.; Liu H.; Jiang L.; Wu H.; Zuo X.; Huang C.; Liu X.; Li F.; Zhang Z.; Liu X.; Dong L.; Li T.; Chen H.; Li J.; He D.; Lu X.; Huang A.; Tao Y.; Wang Y.; Zhang Z.; Wei W.; Li X.; Zeng X.; Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: Sub-analysis of a phase 3 study. Clin Rheumatol  2022,41(3),731-739","journal-title":"Clin Rheumatol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5152\/eurjrheum.2018.18162","volume":"5","author":"Maksymowych W.P.","year":"2018","unstructured":"Maksymowych W.P.; Strand V.; Nash P.; Yazici Y.; Thom H.; Hunger M.; Kalyvas C.; Gandhi K.K.; Porter B.; Jugl S.M.; Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol  2018,5(4),216-223","journal-title":"Eur J Rheumatol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e936600","DOI":"10.12659\/AJCR.936600","volume":"23","author":"Persaud T.","year":"2022","unstructured":"Persaud T.; Morgan R.; Thant H.L.; DeAsis F.J.; Ferre F.; Diaz J.; Adalimumab mitigates lumbar radiculopathy in a case of ankylosing spondylitis. Am J Case Rep  2022,23,e936600","journal-title":"Am J Case Rep"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11926-017-0654-8","volume":"19","author":"Akko\u00e7 N.","year":"2017","unstructured":"Akko\u00e7 N.; Yarkan H.; Kenar G.; Khan M.A.; Ankylosing spondylitis: HLA-B*27-positive versus HLA-B*27-negative disease. Curr Rheumatol Rep  2017,19(5),26","journal-title":"Curr Rheumatol Rep"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"e12913","DOI":"10.1111\/eci.12913","volume":"48","author":"de Koning A.","year":"2018","unstructured":"de Koning A.; Schoones J.W.; van der Heijde D.; van Gaalen F.A.; Pathophysiology of axial spondyloarthritis: Consensus and controversies. Eur J Clin Invest  2018,48(5),e12913","journal-title":"Eur J Clin Invest"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","volume":"79","author":"Blair H.A.","year":"2019","unstructured":"Blair H.A.; Secukinumab: A review in ankylosing spondylitis. Drugs  2019,79(4),433-443","journal-title":"Drugs"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","volume":"7","author":"Zhu W.","year":"2019","unstructured":"Zhu W.; He X.; Cheng K.; Zhang L.; Chen D.; Wang X.; Qiu G.; Cao X.; Weng X.; Ankylosing spondylitis: Etiology, pathogenesis, and treatments. Bone Res  2019,7(1),22","journal-title":"Bone Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"602334","DOI":"10.3389\/fpubh.2020.602334","volume":"8","author":"Tu L.","year":"2020","unstructured":"Tu L.; Xie Y.; Liao Z.; Jiang Y.; Lv Q.; Cao S.; Wei Q.; Gu J.; Cost of illness, quality of life, and work outcomes in active ankylosing spondylitis patients treated with adalimumab in China. Front Public Health  2020,8,602334","journal-title":"Front Public Health"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40744-016-0036-0","volume":"3","author":"Machado M.A.\u00c1.","year":"2016","unstructured":"Machado M.A.\u00c1.; Ferr\u00e9 F.; Moura C.S.; Almeida A.M.; Andrade E.I.G.; Cherchiglia M.L.; Acurcio F.A.; Costs of drug therapy in patients with ankylosing spondylitis in Brazil. Rheumatol Ther  2016,3(2),353-361","journal-title":"Rheumatol Ther"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e0126105","DOI":"10.1371\/journal.pone.0126105","volume":"10","author":"Cooksey R.","year":"2015","unstructured":"Cooksey R.; Husain M.J.; Brophy S.; Davies H.; Rahman M.A.; Atkinson M.D.; Phillips C.J.; Siebert S.; The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data. PLoS One  2015,10(7),e0126105","journal-title":"PLoS One"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212556","volume":"7","author":"Opris-Belinski D.","year":"2018","unstructured":"Opris-Belinski D.; Erdes S.F.; Grazio S.; \u0160enolt L.; Hojnik M.; Nagy O.; Marina D.; Sz\u00e1nt\u00f3 S.; Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: An observational study from five Central and Eastern European countries. Drugs Context  2018,7,1-8","journal-title":"Drugs Context"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1756-185X.13277","volume":"21","author":"Schofield D.","year":"2018","unstructured":"Schofield D.; Shrestha R.; Cunich M.; The economic impacts of using adalimumab (Humira  ) for reducing pain in people with ankylosing spondylitis: A microsimulation study for Australia. Int J Rheum Dis  2018,21(5),1106-1113","journal-title":"Int J Rheum Dis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2217\/cer-2016-0020","volume":"5","author":"Sz\u00e1nt\u00f3 S.","year":"2016","unstructured":"Sz\u00e1nt\u00f3 S.; Po\u00f3r G.; Opris D.; Iaremenko O.; Proch\u00e1zkov\u00e1 L.; Kuuse R.; Nagy O.; Chernyshov V.; G\u00e9her P.; Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central\u2013eastern Europe. J Comp Eff Res  2016,5(5),475-485","journal-title":"J Comp Eff Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3899\/jrheum.131287","volume":"42","author":"Boonen A.","year":"2015","unstructured":"Boonen A.; Boone C.; Albert A.; Mielants H.; Understanding limitations in at-work productivity in patients with active ankylosing spondylitis: The role of work-related contextual factors. J Rheumatol  2015,42(1),93-100","journal-title":"J Rheumatol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/acr.22730","volume":"68","author":"Ortiz C.J.D.","year":"2016","unstructured":"Ortiz C.J.D.; Ramiro S.; Landew\u00e9 R.; van der Heijde D.; Dougados M.; van den Bosch F.; Boonen A.; Work outcome in patients with ankylosing spondylitis: Results from a 12-year followup of an international study. Arthritis Care Res  2016,68(4),544-552","journal-title":"Arthritis Care Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3233\/BMR-169657","volume":"31","author":"Sa\u011f S.","year":"2018","unstructured":"Sa\u011f S.; Nas K.; Sa\u011f M.S.; Tekeo\u011flu \u0130.; Kamanl\u0131 A.; Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis. J Back Musculoskeletal Rehabil  2018,31(3),499-505","journal-title":"J Back Musculoskeletal Rehabil"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/1756-185X.13696","volume":"22","author":"Goh Y.","year":"2019","unstructured":"Goh Y.; Kwan Y.H.; Leung Y.Y.; Fong W.; Cheung P.P.; A cross-sectional study on factors associated with poor work outcomes in patients with axial spondyloarthritis in Singapore. Int J Rheum Dis  2019,22(11),2001-2008","journal-title":"Int J Rheum Dis"},{"key":"ref=90","first-page":"571","volume":"35","author":"Espahbodi S.","year":"2017","unstructured":"Espahbodi S.; Bassett P.; Cavill C.; Freeth M.; Hole J.; Sengupta R.; Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. Clin Exp Rheumatol  2017,35(4),571-578","journal-title":"Clin Exp Rheumatol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/1756-185X.12245","volume":"17","author":"Wang H.","year":"2014","unstructured":"Wang H.; Zuo D.; Sun M.; Hua Y.; Cai Z.; Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: A meta-analysis. Int J Rheum Dis  2014,17(2),142-148","journal-title":"Int J Rheum Dis"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971289295240223095751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/227434\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971289295240223095751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T07:51:34Z","timestamp":1722412294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/227434\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115733971289295240223095751","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}